Gene Solutions, a biotechnology company dedicated to advancing precision oncology in Asia, is proud to announce the presentation of its latest data on the K-TRACK test at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 25 to 30, 2025, in Chicago, IL. The study highlights new data on the K-TRACK test for minimal residual disease (MRD) monitoring in hepatocellular carcinoma (HCC) patients.
In this prospective study, Gene Solutions evaluated the performance of its K-TRACK assay for tracking MRD and predicting relapse in HCC patients undergoing curative-intent liver resection. Top-ranked tumor-specific mutations were selected to monitor circulating tumor DNA (ctDNA) in serial plasma samples over time.
Key findings:
- The K-TRACK assay achieved a pre-operative ctDNA detection rate of 96.6%, significantly outperforming AFP’s 57.6%.
- Post-operative ctDNA positivity was the strongest independent predictor of disease-free survival (HR: 17.9, 95% CI: 5.9–54.1, p<0.001).
- ctDNA monitoring could predict clinical relapse with 82.8% sensitivity, 96.0% specificity, and a lead time of up to 7.3 months — outperforming serum biomarkers such as AFP, AFP-L3, and PIVKA-II.
- The most commonly mutated genes identified were TP53 (42.4%), TERT promoter (39.0%), CTNNB1 (23.7%), and AXIN1 (22.0%).
- The simplified, cost-effective K-TRACK™ assay enabled longitudinal ctDNA monitoring for early relapse detection and prediction of disease-free survival in HCC patients.
Visit our abstract [link here] to explore the full details of this promising research and how K-TRACK could help transform HCC patient care.
The American Association for Cancer Research (AACR), the world’s first and largest cancer research organization, is dedicated to accelerating progress against cancer. The 2025 Annual Meeting will unite tens of thousands of experts under the theme “Unifying Cancer Science and Medicine” to bridge groundbreaking research with real-world patient care.
About Gene Solutions
Gene Solutions, a multinational biotech company in Asia, is leading the way in leveraging advanced AI and ctDNA technologies for innovative cancer detection solutions. The company partners with over 4,500 hospitals and clinics across Southeast Asia and employs a dedicated team of approximately 250 biology experts and technicians out of a total of 700 employees.
With more than 50 peer-reviewed publications and over 50 multi-center studies conducted across the region, Gene Solutions is recognized for its proprietary research and CAP-accredited next-generation sequencing (NGS) laboratories in Singapore and Vietnam. By integrating multi-dimensional genomics with AI-driven methodologies, the company is committed to transforming cancer care and improving patient outcomes.
